Ypsomed : Presentation of Full-Year Results 2025/26

About this update from Ypsomed Holding Ag

Ypsomed Full Year Results 2025/26 Transforming selfcare, Transforming Ypsomed Zurich, 20 May 2026 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements. Making selfcare simpler and easier We benefit from multiple structural growth drivers Selfcare Move from IV to subcutaneous delivery to enhance quality of life, encouraging therapy adherence and lower healthcare cost Biologics Next generation drugs are mostly large molecules that must be injected Biosimilars Expanding access to affordable medical care worldwide Incretins Transforming healthcare and society, improving public health, productivity, and quality of life for millions Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed is now a pure-play self-injection specialist 2026 2025 2025 2024 2023 2022 Phase-out of contract manufacturing delivery systems Completion of the sale of Ypsotec Completion of the sale of the diabetes care business Completion of the sale of the pen needle and blood glucose monitoring business Completion of the sale of the DiaExpert retail business in Germany Transformation from matrix structure to an organization with product areas Thanks to its clear strategic focus, Ypsomed is uniquely positioned to continue to benefit from significant growth Platforms Innovation Operational Excellence Strong Financials Ypsomed offers the broadest range of self-injection solutions on the market Platforms Innovation Operational Excellence Strong Financials Ypsomed offers the broadest range of self-injection solutions on the market Ypsomed won a record number of 44 new projects in FY 2025/26, thereof 12 with new customers New project wins FY 2025/26 Illustrative 44 new project wins Ypsomed wins across the board Various therapeutic areas Originators and biosimilars Developed and emerging markets New and existing pharma customers Sustained growth momentum ahead Incretin Originator Non-incretin Originator Incretin Biosimilar Non-incretin Biosimilar Ypsomed has a diversified customer portfolio with no customer exceeding 15 % of revenue in the foreseeable future Commercial sales by customer FY 2025/26 Illustrative over 130 customers Increasingly diversified portfolio >130 customers No single customer accounts for more than 15 % of commercial revenue Even less concentration at the EBIT level, today and in the foreseeable future Ypsomed supports patients with over 80 approved products in 25 indications 80+ Products approved Pens Diabetes Fertility Growth Disorders Obesity Osteoporosis Parkinson Polycythaemia Vera Hypoparathyroidism Autoinjectors Asthma Alzheimer Atopic Dermatitis ATTR Amyloidosis Hypercholesterolemia Crohn's Disease Migraine Multiple Sclerosis Obesity Oncology Osteoporosis Psoriasis Rheumatoid Arthritis Sexual dysfunction Hereditary Angioedema Fam. Chylomicronemia Syndrome Acromegaly Lupus Neuromyelitis optica spectrum disorder Ypsomed is the innovation leader Platforms Innovation Operational Excellence Strong Financials We announced three new devices platforms in FY 2025/26, all based on Ypsomed's eco-design guidelines YpsoLoop won several awards CPHI innovation award Pharmapack patient-centric design award Red Dot product design award Sustainability is embedded in Ypsomed's products, supply chain, and operations and cements our innovation leadership Eco-designed products Reduce dependencies Carbon-reduced supply chain Meet customer scope 3 requirements Energy-efficient sites Less cost volatility and improved bottom line Clear-to-Clinic accelerates time to market thanks to pre-validated platforms Clinic-ready devices available in <6 months Documentation Verification Parallelization Early readiness Ypsomed expands globally Platforms Innovation Operational Excellence Strong Financials Ypsomed builds a global manufacturing footprint, producing local for local Holly Springs (USA) opening 2027 Schwerin (DE) Schwerin II (DE) opening 2026 Burgdorf HQ (CH) Solothurn (CH) Burgdorf (CH) Burgdorf (CH) Suzhou (CN) (Contract Manuf.) Changzhou (CN) In Solothurn we opened our new tool manufacturing facility in April 2026 And we are phasing out Contract Manufacturing to focus on proprietary autoinjectors until end of 2026 In our Changzhou site commercial production has started end of 2025

View stock analysis, news, and events for Ypsomed Holding Ag